A revolutionary retinal implant in 2025 allowed what percentage of blind participants to read again?

In a remarkable medical advancement in 2025, a revolutionary retinal implant (Review) provided new hope for individuals suffering from severe vision loss. Clinical trials for the innovative PRIMA device demonstrated that an impressive 84% of blind participants were able to read again. This groundbreaking technology specifically targeted geographic atrophy, an advanced form of dry age-related macular degeneration (AMD), which is a leading cause of irreversible central vision loss in older adults.

The PRIMA system involves a tiny, wireless photovoltaic chip, roughly half the thickness of a human hair, implanted beneath the retina. This implant works in conjunction with specialized augmented-reality glasses that feature a camera. The camera captures images and projects them as invisible near-infrared light onto the implant, which then converts these light signals into electrical pulses. These pulses stimulate the remaining healthy retinal cells, effectively bypassing the damaged photoreceptors and transmitting visual information to the brain. Participants in the European trial, published in the New England Journal of Medicine, were able to recognize letters, numbers, and words, with some even reading pages in a book.

This achievement marks a significant milestone in the history of artificial vision. For patients who had lost their central vision, regaining the ability to read represents a profound improvement in their quality of life, restoring independence and confidence. While full 20/20 vision may still be a future goal, the success of the PRIMA implant in enabling functional sight and reading capabilities offers immense promise for continued advancements in treating various forms of blindness.